Partnering

Abimab Partner - Biogen
Abimab Partner - Boehringer Ingelheim
Abimab partner - GSK
Abimab partner - Lilly
Abimab partner - Merck
Abimab partner - Novo_Nordisk
Abimab partner - Regeneron
Abimab partner - Takeda
Abimab partner - Gilead
Abimab Partner - Genentech
Abimab Partner - Bristol-Myers Squibb
Abimab Partner - Alnylam Pharmaceuticals
Abimab Partner - 3T Biosciences
Abimab Partner - Dragonfly
Abimab partner - Kyowa
Abimab partner - Moderna
Abimab partner - ONO PHARMA
Abimab partner - SANOFI
Abimab partner - Vertex
Abimab Partner - curie bio
Abimab Partner - Galderma
Abimab Partner - forte bio
Abimab Partner - IASO Biotherapeutics
Abimab Partner - Iconic Therapeutics
Abimab Partner - Immunitas
Abimab Partner - IGM
Abimab Partner - IOmix
Abimab Partner - Iteos
Abimab Partner - Janssen
Abimab Partner - Kite Pharma
Abimab Partner - MDAnderson_logo
Abimab Partner - memorial sloan kettering logo
Abimab Partner - Mersana
Abimab Partner - Mestag Therapeutics
Abimab Partner - Innovent
Abimab Partner - Werewolf Therapeutics
Abimab Partner - Scholar Rock
Abimab Partner - Seagen
Abimab Partner - Senseibio
Abimab Partner - Solve Tx
Placeholder for partner logo
Placeholder for partner logo
Placeholder for partner logo
Placeholder for partner logo
Abimab Partner - Therini
Abimab Partner - Tizona
Abimab Partner - Trishulatx
Abimab Partner - Triveni
Placeholder for partner logo
Placeholder for partner logo
Placeholder for partner logo
Placeholder for partner logo

How We Partner

Adimab is a technology company and does not have an internal pipeline. We are solely focused on the success of our partners. Therefore, we approach every single project as if it were our own.

115+

Therapeutic Partners

500+

Therapeutic Programs

70+

Clinical Advancements

5

Approved Products and Blas  Filed

Funded Discovery

Adimab generates therapeutic leads on targets selected by our partners. We have performed over 330 funded discovery projects for IgG and HCAb discovery, engineering, multispecifics (including T cell engagers), and therapeutic leads for complex targets, such as GPCRs.

 

Adimab works closely with our partners to identify goals for each project and meets monthly to review all work performed. Initial delivery of a panel of full IgG and/or HCAb protein and the corresponding sequences, plus comprehensive characterization data, is typically within 4 months. Our partners perform functional assessment of the delivered antibodies. Leads with desired functional properties can continue to be engineered to generate the highest quality therapeutics.

Platform Transfer

Adimab has transferred our proprietary yeast-based platform to six major pharmaceutical companies. These are large partnerships where Adimab trains and fully enables our partners to use the platform in the pharma company’s labs. Our partners have unique library diversities and therefore can work on any target of their choice and as many targets of their choice. Our transfer partners also have access to use our platform for engineering IgGs and other modalities, generating numerous types of multispecifics, and to find leads for complex targets. Our transfer partners have advanced more than 200 programs through the use of our proprietary platform.


Adimab also holds regular conferences for our platform transfer partners, where we fly scientists to a designated site (e.g. Iceland, England, Vermont) for 3 days of presentations and round table discussions. It has developed into an amazing community that allows for a deeper level of sharing and learning for all involved.

Non-exclusive Programs

Adimab has several programs that we license non-exclusively. Our T cell engager modules (CD3 and CD28) have been partnered with more than 20 companies. Our heterodimerization solutions for enabling numerous multispecific constructs have been partnered with more than 15 companies.

Scroll to Top